Recently, SQLE upregulation was reported and identified as a prognostic marker in a variety of disease, such as non-alcoholic steatohepatitis 26, hepatocellular carcinoma 27 and breast cancer 28. Here, SQLE is linked to metabolic dysfunction-associated steatohepatitis.